WO2003076404A1 - Thioester d'acide oligolactique en chaine - Google Patents
Thioester d'acide oligolactique en chaine Download PDFInfo
- Publication number
- WO2003076404A1 WO2003076404A1 PCT/JP2003/001696 JP0301696W WO03076404A1 WO 2003076404 A1 WO2003076404 A1 WO 2003076404A1 JP 0301696 W JP0301696 W JP 0301696W WO 03076404 A1 WO03076404 A1 WO 03076404A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- group
- compound
- formula
- compound represented
- lactic acid
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
- C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
- C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D213/62—Oxygen or sulfur atoms
- C07D213/70—Sulfur atoms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4164—1,3-Diazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4402—Non condensed pyridines; Hydrogenated derivatives thereof only substituted in position 2, e.g. pheniramine, bisacodyl
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/695—Silicon compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C327/00—Thiocarboxylic acids
- C07C327/20—Esters of monothiocarboxylic acids
- C07C327/22—Esters of monothiocarboxylic acids having carbon atoms of esterified thiocarboxyl groups bound to hydrogen atoms or to acyclic carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
- C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
- C07D233/66—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D233/84—Sulfur atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F7/00—Compounds containing elements of Groups 4 or 14 of the Periodic System
- C07F7/02—Silicon compounds
- C07F7/08—Compounds having one or more C—Si linkages
- C07F7/18—Compounds having one or more C—Si linkages as well as one or more C—O—Si linkages
- C07F7/1804—Compounds having Si-O-C linkages
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02P—CLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
- Y02P20/00—Technologies relating to chemical industry
- Y02P20/50—Improvements relating to the production of bulk chemicals
- Y02P20/55—Design of synthesis routes, e.g. reducing the use of auxiliary or protecting groups
Definitions
- the present invention relates to a linear oligolactic acid thioester and a method for producing the same. More specifically, the present invention relates to a chain oligoester thioester having a thioester group at a terminal, and a method for producing the same.
- Cyclic and / or chain poly-L-lactic acid mixtures having a degree of condensation of 3 to 19 can be used as antineoplastic agents (JP-A-9-227388 and JP-A-10-13015). 3) and as a QOL improver for cancer patients (Japanese Patent Application No. 11-39,894; Japanese Journal of Cancer Therapy Vol. 33, No. 3, page 493) Is reported.
- the cyclic and / or chain polylactic acid mixture having a condensation degree of 3 to 19 has a hypoglycemic effect and is useful as a drug for preventing and / or treating diabetes or diabetic complications. (Japanese Patent Application No. 111-224883), which is also useful for suppressing excessive appetite, promoting basal metabolism, improving obesity and preventing or preventing Z or Z. I have.
- cyclic and / or chain oligolactic acid mixtures having a condensation degree of 3 to 19 are being demonstrated to exhibit a wide variety of medicinal effects, and are expected to be developed as pharmaceuticals in the future .
- polylactic acid having a specific chain length as a single compound For the purpose of isolating polylactic acid having a specific chain length as a single compound, attempts have been made to synthesize a chain oligolactic acid ester having a degree of condensation of 3 to 20 by esterifying a terminal carboxyl group.
- the present inventors have conducted intensive studies in order to solve the above-mentioned problems, and as a result, using lactic acid as a starting material and reacting it with a disulfide compound, a linear oligolactic acid thioester having a thioester group at the terminal is obtained.
- a linear oligolactic acid thioester having a thioester group at the terminal is obtained.
- the present invention has been completed based on this finding.
- X represents a hydrogen atom or a hydroxyl-protecting group
- Y represents an aliphatic group, an aryl group, or a heterocyclic group
- n represents an integer of 0 to 19
- n represents an integer of 0 to 5, and particularly preferably, n is 0 or 2.
- Y is a heterocyclic group, more preferably, Y is a 5- to 10-membered aromatic heterocyclic group containing 1 or 2 heteroatoms, particularly preferably, Y is And a pyridyl group or a (4-tributyl-1 ⁇ -isopropyl) imidazolyl group.
- a compound represented by the formula CH 3 CH (OX) COOH (where X represents a hydrogen atom or a protecting group for a hydroxyl group), and a compound represented by the formula Y—S—S—Y ( formula Wherein Y represents an aliphatic group, an aryl group or a heterocyclic group), and producing a compound represented by the formula CH 3 CH (OX) CO—S—Y
- X represents a hydrogen atom or a protecting group for a hydroxyl group
- Y—S—S—Y formula Wherein Y represents an aliphatic group, an aryl group or a heterocyclic group
- X represents a hydrogen atom or a protecting group of hydroxyl group
- CH 3 CH (OX) COOCH (CH 3) COO H with a compound represented by the formula CH 3
- Y represents an aliphatic group, an aryl group or a heterocyclic group
- CH 3 CH (OX) COOCH (CH 3 ) COOCH (CH 3 ) CO—S—Y wherein X represents a hydrogen atom or a hydroxyl-protecting group, and Y represents an aliphatic group, an aryl group or a heterocyclic group
- the present invention relates to a compound represented by the following general formula (1) or a salt thereof.
- X represents a hydrogen atom or a hydroxyl-protecting group
- Y represents an aliphatic group, an aryl group or a heterocyclic group
- n represents 0 or an integer of 19
- the type of the protecting group for the hydroxyl group represented by X is not particularly limited, and can be appropriately selected by those skilled in the art.
- Specific examples of the hydroxyl-protecting group include the following.
- the type of the aliphatic group, aryl group or heterocyclic group represented by Y is not particularly limited.
- aliphatic group in the present invention a lower alkyl group, a lower alkenyl group or And higher alkynyl groups.
- carbon number of the aliphatic group is not particularly limited, it is generally 1 to 10, preferably 1 to 6, and more preferably 1 to 4.
- the chain type of the aliphatic group is not particularly limited, and may be any of a linear chain, a branched chain, a cyclic chain, or a combination thereof.
- a lower alkyl group is particularly preferred.
- Specific examples of lower alkyl groups include methyl, ethyl, propyl, isopropyl, cyclopropyl, butyl, isobutyl, sec-butyl, tert-butyl, cyclopropylmethyl, cyclobutyl , A pentyl group and a hexyl group.
- the aryl group in the present invention is an aryl group having 6 to 24 carbon atoms, preferably 6 to 12 carbon atoms, and the aryl group may have one or more substituents.
- Specific examples of aryl groups include, for example, phenyl, naphthyl, p-methoxyphenyl and the like.
- the heterocyclic group in the present invention is a 5- to 10-membered saturated or unsaturated monocyclic or condensed ring containing at least one oxygen atom, nitrogen atom or sulfur atom.
- Specific examples of the heterocyclic group include, for example, pyridyl, imidazolyl, quinolyl, isoquinolyl, pyrimidinyl, pyrazul, pyridazinyl, phthalazinyl, triazinyl, furyl, chenyl, pyrrolyl, thixazolyl, thiazolyl, thiadiazolyl, triazolyl, triazolyl Imidazolinole, pyrrolidino, morpholino and the like.
- these hetero rings may have one or more substituents.
- Examples of the substituent which the aryl group or heterocyclic group may have include a halogen atom (fluorine, chlorine, bromine, or iodine), an alkyl group, an aryl group, a carboxamide group, an alkylsulfonamide group, Arylsulfonamide, alkoxy, aryloxy, alkylthio, arylthio, carpamoyl, sulfamoyl, cyano, alkylsulfonyl, arylsulfonyl, alkoxycarbonyl, aryloxycarbo- And a hydroxyl group.
- a halogen atom fluorine, chlorine, bromine, or iodine
- Y is preferably an aromatic group, and particularly preferably, Y is a 5- to 10-membered aromatic heterocyclic group containing one or two hetero atoms. Most preferably, Y is a pyridyl group or a (4-4--butyl-N-isopropyl) imidazolyl group.
- ⁇ represents an integer of 0 to 19. When ⁇ is 0, it becomes a monomer of lactic acid, when ⁇ is 1, it becomes a dimer of lactic acid, when ⁇ is 2, it becomes a trimer of lactic acid, and when ⁇ is 3, it becomes a trimer of lactic acid. When ⁇ is 19 in the same manner, it becomes a 20-mer of lactic acid.
- ⁇ preferably represents an integer of 0 to 5, and in a particularly preferred embodiment, ⁇ is 0 or 2.
- the compound of the present invention can also exist as a metal salt.
- a metal salt include an alkali metal salt such as a sodium salt and a potassium salt, and magnesium. Salts, alkaline earth metal salts such as calcium salts, aluminum salts, zinc salts and the like.
- the compounds of the present invention contain asymmetric carbon atoms, stereoisomers exist, and all possible isomers and mixtures containing two or more of these isomers in any ratio are within the scope of the present invention. Things. That is, the compound of the present invention includes a mixture of various optical isomers such as an optically active substance, a racemate and a diastereomer, and an isolated form thereof.
- the configuration of the compound of the present invention depends on the configuration of a lactic acid unit in the compound used as a raw material. That is, the configuration of the compound of the present invention varies depending on whether the L-form, the D-form or a mixture thereof is used as the lactic acid unit in the compound used as a raw material. In the present invention, it is preferable to use the L-form as the configuration of the lactic acid unit.
- the compound represented by CH 3 CH (OX) CO-S—Y corresponding to the compound in which ⁇ is 0 is CH.
- CH (OX) COOH where X is a hydrogen source Reacting with a compound represented by the general formula Y—S—S—Y (wherein Y represents an aliphatic group, an aryl group or a heterocyclic group) Can be manufactured.
- L-lactic acid As CH 3 CH (OX) COOH used as a starting material, L-lactic acid, D-lactic acid, or a mixture thereof can be used. The hydroxyl group in lactic acid may be protected.
- the reaction temperature is not particularly limited as long as the reaction proceeds, but is preferably from 1100 ° C to room temperature.
- the reaction is preferably performed in the presence of a reaction solvent.
- the reaction solvent is not particularly limited as long as it is an inert solvent for the reaction, but is preferably an aromatic hydrocarbon solvent such as benzene, toluene, xylene, and ethylbenzene, tetrahydrofuran (THF), getyl ether, and dimethoxetane. Can be used.
- reaction atmosphere an inert gas atmosphere such as nitrogen gas or argon gas can be used.
- a toluene solution of triphenylphosphine is added to a toluene solution of L-lactic acid, and a compound represented by the formula Y—S—S—Y (for example, pyridyl disulfide or 2,2-bis- (4- --butyl-N-isopropyl) imidazo Toluene solution) and stirred for 15 hours. After concentration under reduced pressure, add water and extract several times with black-mouthed form.
- Y—S—S—Y for example, pyridyl disulfide or 2,2-bis- (4- --butyl-N-isopropyl) imidazo Toluene solution
- CH 3 CH (OX) CO OCH (CH 3 ) CO—S—Y which corresponds to the compound in which n is 1 in the general formula (1), is used as a starting material for CH 3 CH (OX) COOH
- CH 3 CH (OX) COOCH (CH 3 ) CO OH By using CH 3 CH (OX) COOCH (CH 3 ) CO OH instead of using, as described above, by reacting with the compound represented by the formula Y—S—S—Y be able to.
- the compound represented by the formula CH 3 CH (OX) COOCH (CH 3 ) COOH (wherein X represents a hydrogen atom or a hydroxyl-protecting group) is lactoyl lactic acid optionally protected with a hydroxyl group.
- X represents a hydrogen atom or a hydroxyl-protecting group
- the esterification reaction may be, for example, a solution containing the formula CH 3 CH (OX) COOCH ( CH 3) a compound represented by C OOH, after stirring added cyclohexyl Cal positive imide solution dicyclohexyl formula CH 3 CH ( OH) CO—S—Y can be carried out by adding a solution of the compound represented by S—Y and a dimethylaminopyridine solution and stirring for a certain period of time.
- the reaction temperature is not particularly limited as long as the reaction proceeds, but is preferably from 1100 ° C to room temperature.
- the reaction is preferably carried out in the presence of a reaction solvent.
- the reaction solvent is not particularly limited as long as it is a solvent inert to the reaction, and preferably, toluene, benzene, xylene, alkylbenzene, tetrahydrofuran (THF), ethynoleatel, dimethoxetane, or the like can be used.
- an inert gas atmosphere such as a nitrogen gas or an argon gas can be used.
- a compound in which n is 0, 1 or 2 in the general formula (1) can be produced.
- a thioester compound containing a desired number of lactic acid units is used as a starting material for the compound in which n is 3, and this is represented by the formula CH 3 CH (OX) COOCH (CH 3 ) COOH (wherein X represents a protecting group for a hydroxyl group).
- Example Example 1 Synthesis of L-lactic acid pyridyl thiol ester
- the obtained product was directly used for the next reaction.
- the present invention it has become possible to provide a linear oligolactic acid thioester having a thioester group at a terminal as a single compound.
- the oligolactic acid thioester It will be possible to develop Teru as pharmaceuticals, pharmaceutical ingredients, food additives, cosmetic ingredients, pharmaceutical ingredients, and pharmaceutical additives.
Description
Claims
Priority Applications (6)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US10/503,582 US20050222420A1 (en) | 2002-02-19 | 2003-02-18 | Chain oligolactic acid thioester |
CA002480001A CA2480001A1 (en) | 2002-02-19 | 2003-02-18 | Chain oligolactic acid thioester |
KR10-2004-7012861A KR20040085202A (ko) | 2002-02-19 | 2003-02-18 | 쇄상 올리고유산 티오에스테르 |
EP03705267A EP1484319A4 (en) | 2002-02-19 | 2003-02-18 | CHAIN OLIGOMIC ACID ETHANOL |
JP2003574625A JPWO2003076404A1 (ja) | 2002-02-19 | 2003-02-18 | 鎖状オリゴ乳酸チオエステル |
AU2003211386A AU2003211386A1 (en) | 2002-02-19 | 2003-02-18 | Chain oligolactic acid thioester |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2002042008 | 2002-02-19 | ||
JP2002-42008 | 2002-02-19 |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2003076404A1 true WO2003076404A1 (fr) | 2003-09-18 |
Family
ID=27799986
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/JP2003/001696 WO2003076404A1 (fr) | 2002-02-19 | 2003-02-18 | Thioester d'acide oligolactique en chaine |
Country Status (10)
Country | Link |
---|---|
US (1) | US20050222420A1 (ja) |
EP (1) | EP1484319A4 (ja) |
JP (1) | JPWO2003076404A1 (ja) |
KR (1) | KR20040085202A (ja) |
CN (1) | CN1646492A (ja) |
AU (1) | AU2003211386A1 (ja) |
CA (1) | CA2480001A1 (ja) |
RU (1) | RU2004127918A (ja) |
TW (1) | TW200303299A (ja) |
WO (1) | WO2003076404A1 (ja) |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2005290255A (ja) * | 2004-04-01 | 2005-10-20 | Sanyo Chem Ind Ltd | ポリエステル樹脂配合用エステル化合物 |
Families Citing this family (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
RU2527471C1 (ru) * | 2013-04-19 | 2014-08-27 | Федеральное государственное унитарное предприятие "Научно-исследовательский институт химии и технологии полимеров имени академика В.А. Каргина с опытным заводом" (ФГУП "НИИ полимеров") | Полиэфирполикарбонаты олигомолочной кислоты |
Citations (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPS5094172A (ja) * | 1973-12-24 | 1975-07-26 | ||
JPS51125740A (en) * | 1975-02-25 | 1976-11-02 | Mitsui Toatsu Chem Inc | A weedkiller |
US4115100A (en) * | 1976-03-05 | 1978-09-19 | Ciba-Geigy Corporation | Selective herbicidal composition containing 2-pyridinol compounds |
US4257801A (en) * | 1977-03-09 | 1981-03-24 | Imperial Chemical Industries Limited | Cotton desiccation with phenoxyalkanoic acids |
US4404020A (en) * | 1975-08-25 | 1983-09-13 | Ciba-Geigy Corporation | Certain esters of 2-[(2,6-dichloro-3-pyridyl)oxy]propionic acid, compositions containing same and their herbicidal properties |
JPS60149554A (ja) * | 1984-01-13 | 1985-08-07 | Hokko Chem Ind Co Ltd | 3,4−ジクロルベンジルチオ−ルエステル誘導体および土壌殺菌剤 |
EP1224936A1 (en) * | 1999-09-20 | 2002-07-24 | Amato Pharmaceutical Products, Ltd. | Physical strength enhancing agents and glycogen accumulation promoting agents |
JP2002265420A (ja) * | 2001-03-13 | 2002-09-18 | Tendou Seiyaku Kk | 鎖状オリゴ乳酸エステル |
Family Cites Families (9)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR20020068497A (ko) * | 1999-08-09 | 2002-08-27 | 아마토 세이야쿠 가부시키가이샤 | 당뇨병 치료제 |
CA2385321A1 (en) * | 1999-09-20 | 2001-03-29 | Mikio Watanabe | Method for producing cyclic lactic acid oligomer |
EP1219616A4 (en) * | 1999-09-20 | 2002-11-06 | Amato Pharm Prod Ltd | PROCESS FOR THE PREPARATION OF CYCLIC LACTIC ACID OLIGOMERS |
CN1433315A (zh) * | 1999-12-03 | 2003-07-30 | 天藤制药株式会社 | 放射线防护剂 |
EP1250928A1 (en) * | 2000-01-26 | 2002-10-23 | Amato Pharmaceutical Products, Ltd. | Cancer cell implantation inhibitors |
KR20030070101A (ko) * | 2001-01-12 | 2003-08-27 | 아마토 세이야쿠 가부시키가이샤 | 미생물 감염 방지제 |
CN1496266A (zh) * | 2001-01-12 | 2004-05-12 | ������ҩ��ʽ���� | 抗变态反应剂 |
KR20030070137A (ko) * | 2001-01-24 | 2003-08-27 | 아마토 세이야쿠 가부시키가이샤 | 항스트레스제 |
JP2002275256A (ja) * | 2001-03-19 | 2002-09-25 | Tendou Seiyaku Kk | 乳酸オリゴマーの製造方法 |
-
2003
- 2003-02-18 TW TW092103323A patent/TW200303299A/zh unknown
- 2003-02-18 EP EP03705267A patent/EP1484319A4/en not_active Withdrawn
- 2003-02-18 RU RU2004127918/04A patent/RU2004127918A/ru not_active Application Discontinuation
- 2003-02-18 AU AU2003211386A patent/AU2003211386A1/en not_active Abandoned
- 2003-02-18 KR KR10-2004-7012861A patent/KR20040085202A/ko not_active Application Discontinuation
- 2003-02-18 JP JP2003574625A patent/JPWO2003076404A1/ja active Pending
- 2003-02-18 CA CA002480001A patent/CA2480001A1/en not_active Abandoned
- 2003-02-18 CN CNA038087715A patent/CN1646492A/zh active Pending
- 2003-02-18 US US10/503,582 patent/US20050222420A1/en not_active Abandoned
- 2003-02-18 WO PCT/JP2003/001696 patent/WO2003076404A1/ja not_active Application Discontinuation
Patent Citations (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPS5094172A (ja) * | 1973-12-24 | 1975-07-26 | ||
JPS51125740A (en) * | 1975-02-25 | 1976-11-02 | Mitsui Toatsu Chem Inc | A weedkiller |
US4404020A (en) * | 1975-08-25 | 1983-09-13 | Ciba-Geigy Corporation | Certain esters of 2-[(2,6-dichloro-3-pyridyl)oxy]propionic acid, compositions containing same and their herbicidal properties |
US4115100A (en) * | 1976-03-05 | 1978-09-19 | Ciba-Geigy Corporation | Selective herbicidal composition containing 2-pyridinol compounds |
US4257801A (en) * | 1977-03-09 | 1981-03-24 | Imperial Chemical Industries Limited | Cotton desiccation with phenoxyalkanoic acids |
JPS60149554A (ja) * | 1984-01-13 | 1985-08-07 | Hokko Chem Ind Co Ltd | 3,4−ジクロルベンジルチオ−ルエステル誘導体および土壌殺菌剤 |
EP1224936A1 (en) * | 1999-09-20 | 2002-07-24 | Amato Pharmaceutical Products, Ltd. | Physical strength enhancing agents and glycogen accumulation promoting agents |
JP2002265420A (ja) * | 2001-03-13 | 2002-09-18 | Tendou Seiyaku Kk | 鎖状オリゴ乳酸エステル |
Non-Patent Citations (2)
Title |
---|
BERENGUER R. ET AL.: "Enantioselective synthesis of alpha-hydroxy thioesters viaoxazaborolidine-mediated reduction of alpha-phenylthio-enones", TETRAHEDRON LETTERS, vol. 39, no. 15, 1998, pages 2183 - 2186, XP004110664 * |
See also references of EP1484319A4 * |
Cited By (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2005290255A (ja) * | 2004-04-01 | 2005-10-20 | Sanyo Chem Ind Ltd | ポリエステル樹脂配合用エステル化合物 |
JP4655496B2 (ja) * | 2004-04-01 | 2011-03-23 | 東レ株式会社 | ポリエステル樹脂配合用エステル化合物 |
Also Published As
Publication number | Publication date |
---|---|
CA2480001A1 (en) | 2003-09-18 |
JPWO2003076404A1 (ja) | 2005-07-07 |
US20050222420A1 (en) | 2005-10-06 |
RU2004127918A (ru) | 2005-04-10 |
CN1646492A (zh) | 2005-07-27 |
EP1484319A1 (en) | 2004-12-08 |
TW200303299A (en) | 2003-09-01 |
EP1484319A4 (en) | 2007-01-24 |
AU2003211386A1 (en) | 2003-09-22 |
KR20040085202A (ko) | 2004-10-07 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JP3295879B2 (ja) | タキサン誘導体の製造方法 | |
US6025516A (en) | Resolution of 2-hydroxy-3-amino-3-phenylpropionamide and its conversion to C-13 sidechain of taxanes | |
JP4800205B2 (ja) | 五環性タキサンの製造方法 | |
JP3423002B2 (ja) | タキサン誘導体、その調製、及びそれを含有する処方物 | |
JP2002265420A (ja) | 鎖状オリゴ乳酸エステル | |
WO2003076404A1 (fr) | Thioester d'acide oligolactique en chaine | |
JPH01275588A (ja) | キラル3‐ベータ水素(3r)4‐アロイロキシアゼチジノンの合成方法 | |
JP4621429B2 (ja) | 乳酸誘導体 | |
WO2003070684A1 (fr) | Procede de production d'un ester d'acide oligolactique a chaine | |
JP4445769B2 (ja) | 側鎖にヒドロキシルエチル基を有するオリゴ乳酸エステル | |
CN111320579B (zh) | 一种8-酰胺-5-卤代喹啉衍生物的制备方法 | |
JP2010270145A (ja) | 14位で官能化されたタキサン誘導体及びその製造方法 | |
KR101491007B1 (ko) | 에제티밉 중간체의 제조방법 | |
JP4643474B2 (ja) | 1置換コハク酸イミドの製造方法 | |
KR100502833B1 (ko) | 심바스타틴 및 이의 중간체 화합물들의 개선된 제조방법 | |
CN113845481A (zh) | 一种4,4-二甲基-4,5-二氢哒嗪-3-酮的合成方法 | |
JPWO2003035605A1 (ja) | 新規化合物及びその製造方法 | |
JP4483183B2 (ja) | 6,7−ジヒドロキシクマリン−3−カルボン酸誘導体の製法及びその中間体 | |
JPH05213922A (ja) | ラクトン誘導体の新規製造方法 | |
JPH06145119A (ja) | 光学活性なβ−アミノ酸エステルの製造法 | |
JPH04264082A (ja) | 新規なオキセタノシルマレイミド誘導体及びその製造法 | |
JPH0859609A (ja) | 4−アシルオキシ−2−アゼチジノン誘導体の新規製造方法 | |
JP2001048842A (ja) | オキソエステル化合物とその製造方法 | |
JP2009256376A (ja) | 3−アルコキシカルボニル−6,7−クロロメチレンジオキシクマリン化合物、及びその製造方法。 | |
JP2003267964A (ja) | 6,7−ジヒドロキシクマリンの製造法及びその中間体 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AK | Designated states |
Kind code of ref document: A1 Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ OM PH PL PT RO RU SC SD SE SG SK SL TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW |
|
AL | Designated countries for regional patents |
Kind code of ref document: A1 Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IT LU MC NL PT SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG |
|
DFPE | Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101) | ||
121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
WWE | Wipo information: entry into national phase |
Ref document number: 2003574625 Country of ref document: JP |
|
WWE | Wipo information: entry into national phase |
Ref document number: 1020047012861 Country of ref document: KR |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2003211386 Country of ref document: AU |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2003705267 Country of ref document: EP |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2004127918 Country of ref document: RU Ref document number: 2480001 Country of ref document: CA |
|
WWE | Wipo information: entry into national phase |
Ref document number: 20038087715 Country of ref document: CN |
|
WWP | Wipo information: published in national office |
Ref document number: 2003705267 Country of ref document: EP |
|
WWE | Wipo information: entry into national phase |
Ref document number: 10503582 Country of ref document: US |
|
WWW | Wipo information: withdrawn in national office |
Ref document number: 2003705267 Country of ref document: EP |